CommercialCoverageMedium impact
08.02.03a, Etranacogene dezaparvovec-drlb (Hemgenix®)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
This is a reissue of the policy for Etranacogene dezaparvovec-drlb (Hemgenix®), a gene therapy for hemophilia B. The policy is being reposted with an effective date of May 28, 2025, indicating updated coverage or billing requirements for this specialized pharmaceutical treatment.
Action Required
Before May 28, 2025: Billing team should review the complete updated policy for Hemgenix® gene therapy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures. Update billing protocols and staff training accordingly for this specialized hemophilia B treatment.